『Innovating Clinical Trials』のカバーアート

Innovating Clinical Trials

Innovating Clinical Trials

著者： Liam Eves and Ted Trafford
無料で聴く

概要

Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

Ted Trafford - https://probitymedical.com/
With 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 75+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.

Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.



Opinions expressed are those of the participants and not their employers.

© 2026 Innovating Clinical Trials 生物科学 科学
エピソード
  • ICT Ep 2.11: The Top 10 Signs Your Site Feasibility Process Is Off Track

    ICT Ep 2.11: The Top 10 Signs Your Site Feasibility Process Is Off Track
    2026/03/11

    Using a David Letterman-inspired “Top 10” format, the conversation highlights common feasibility pitfalls faced by sponsors, CROs, and clinical trial sites, including overly complex questionnaires, unrealistic enrollment expectations, delayed communication, and last-minute fire drills.

    The discussion goes beyond surface-level frustration to explore how sponsors and CROs can rethink clinical trial site feasibility by simplifying processes, questioning legacy requirements, and focusing on identifying and supporting sites with the highest potential for success. Ted and Liam also examine how better feasibility strategy can improve enrollment outcomes, reduce operational burden, and ultimately lead to more efficient clinical trials.

    This episode is for professionals involved in site feasibility, trial startup, enrollment strategy, and clinical operations, and for those who want to move beyond broken processes and drive better trial performance.
    続きを読む 一部表示
    10 分
  • ICT Ep 2.10 Where Clinical Trials Break Down, Even With Good Teams

    ICT Ep 2.10 Where Clinical Trials Break Down, Even With Good Teams
    2026/03/04

    Why do clinical trials struggle even when teams are experienced and well-intentioned?

    In this episode, Liam and Ted explore why these outcomes are rarely about individual performance and far more often about system-level misalignments. They unpack how incentives, information flow, and decision rights across sponsors, CROs, and sites shape behaviour and why execution tends to break down logically, not randomly.

    The discussion reframes “execution issues” as predictable outcomes of how trials are designed and governed, offering a clearer lens for understanding why good teams can still produce fragile results.
    続きを読む 一部表示
    18 分
  • ICT EP 2.9: Designing Eligibility Criteria That Work in the Real World

    ICT EP 2.9: Designing Eligibility Criteria That Work in the Real World
    2026/02/18

    Eligibility criteria are meant to bring clarity to clinical trials, but in practice, they often do the opposite.

    In this episode of Innovating Clinical Trials, Liam and Ted unpack how poorly worded, ambiguous, or misaligned eligibility criteria quietly slow enrollment, frustrate sites, and introduce risk later in development.

    They explore:

    - Why small wording choices create big downstream problems

    - How “gray areas” force sites into interpretation rather than execution

    - The disconnect between healthcare documentation and research expectations

    - Why enrollment challenges often originate long before the first patient is screened

    - What sponsors can do to design criteria that work in the real world- not just on paper

    This conversation is a practical reflection on how better protocol design can remove friction, protect sites, and keep trials moving.
    続きを読む 一部表示
    18 分
まだレビューはありません